Retatrutide, by Soma, represents a promising breakthrough in metabolic control . This dual-action drug combines GLP-1 receptor activity with GIP receptor agonist activation , demonstrating substantial potential in patient findings for body reduction . Experts believe Retatrutide could provide a new solution for individuals experiencing excess weigh